We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
(+41%)
Cap. Flow
+$327M
Cap. Flow
% of AUM
38.29%
Top 10 Holdings %
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$13.6M |
| 2 |
Merck
MRK
|
+$12.5M |
| 3 |
Intuitive Surgical
ISRG
|
+$11.1M |
| 4 |
DOCU
DocuSign
DOCU
|
+$10.9M |
| 5 |
Insulet
PODD
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nasdaq
NDAQ
|
+$7.26M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$6.86M |
| 3 |
Incyte
INCY
|
+$6.31M |
| 4 |
Fidelity National Information Services
FIS
|
+$5.73M |
| 5 |
AbbVie
ABBV
|
+$4.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.41% |
| 2 | Consumer Discretionary | 17.68% |
| 3 | Healthcare | 16.13% |
| 4 | Industrials | 12.13% |
| 5 | Financials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Constellation Brands
STZ
$22.4B
| $682K | 0.08% |
+2,713
| New | +$708K |
|
|
ETRN
327
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $681K | 0.08% |
+72,726
| New | +$694K |
|
328
Robert Half
RHI
$4.19B
| $681K | 0.08% |
+9,299
| New | +$706K |
|
329
Valvoline
VVV
$5.01B
| $681K | 0.08% |
+21,118
| New | +$742K |
|
330
Ultragenyx Pharmaceutical
RARE
$2.54B
| $680K | 0.08% |
19,075
+5,271
| +38% | +$209K |
|
331
Vicor
VICR
$10.4B
| $676K | 0.08% |
+11,473
| New | +$760K |
|
332
Ares Management
ARES
$32.2B
| $674K | 0.08% |
+6,551
| New | +$662K |
|
|
SGI
333
Somnigroup International
SGI
$14.7B
| $667K | 0.08% |
+15,386
| New | +$682K |
|
334
Amcor
AMCR
$21.8B
| $666K | 0.08% |
14,533
+629
| +5% | +$30.3K |
|
335
Cintas
CTAS
$81.5B
| $659K | 0.08% |
5,480
+1,032
| +23% | +$128K |
|
336
Arrowhead Research
ARWR
$12.6B
| $658K | 0.08% |
24,474
+11,764
| +93% | +$360K |
|
337
LKQ Corp
LKQ
$6.2B
| $657K | 0.08% |
+13,278
| New | +$711K |
|
338
Enbridge
ENB
$117B
| $657K | 0.08% |
+19,794
| New | +$703K |
|
339
Navitas Semiconductor
NVTS
$3.31B
| $653K | 0.08% |
94,018
+74,737
| +388% | +$662K |
|
340
Petrobras Class A
PBR.A
$107B
| $641K | 0.08% |
46,761
-194,413
| -81% | -$2.51M |
|
341
Oxford Industries
OXM
$579M
| $638K | 0.07% |
+6,641
| New | +$674K |
|
|
EFOR
342
Everforth Inc
EFOR
$1.26B
| $636K | 0.07% |
+7,784
| New | +$620K |
|
|
GMS
343
DELISTED
GMS Inc
GMS
| $634K | 0.07% |
+9,907
| New | +$687K |
|
344
DT Midstream
DTM
$13.8B
| $630K | 0.07% |
+11,912
| New | +$621K |
|
345
Equinor
EQNR
$93.1B
| $627K | 0.07% |
+19,132
| New | +$593K |
|
|
CBAY
346
DELISTED
Cymabay Therapeutics
CBAY
| $620K | 0.07% |
+41,556
| New | +$551K |
|
347
ScottsMiracle-Gro
SMG
$3.86B
| $616K | 0.07% |
+11,917
| New | +$690K |
|
348
BellRing Brands
BRBR
$1.48B
| $615K | 0.07% |
14,925
+7,716
| +107% | +$296K |
|
349
Veeva Systems
VEEV
$34.4B
| $613K | 0.07% |
+3,014
| New | +$607K |
|
350
Air Products & Chemicals
APD
$65.6B
| $608K | 0.07% |
2,146
+691
| +47% | +$203K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.
- Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
- Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
- Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
- Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
- Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
- Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
- Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.
Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.